- Supernus completes acquisition/merger with Indivior to form expanded CNS biopharma company.
- Indivior shareholders to receive aggregate $1.0B one-time special cash dividend.
- Transaction supported by a $650M term loan facility via Citibank plus balance sheet cash.
?? Positive AI Sentiment (+6.5 / 10)